ACRX
AcelRx Pharmaceuticals Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-02-2018 | 08-02-2018 after market close | 05-09-2018 after market close | 03-08-2018 after market close | 11-09-2017 after market close | 08-01-2017 after market close | 05-08-2017 after market close | |
|---|---|---|---|---|---|---|---|
| Actual EPS | -0.21 | -0.2 | -0.23 | -0.2 | -0.28 | -0.29 | -0.34 |
| Consensus EPS | -0.2 | -0.19 | -0.24 | -0.2 | -0.26 | -0.28 | -0.28 |
| Estimated EPS | -0.2 | -0.19 | -0.24 | -0.2 | -0.26 | -0.28 | -0.28 |
| Number of Estimates | 4 | 3 | 2 | 1 | 5 | 5 | 5 |
| EPS Surprise | -$0.01 | -$0.01 | $0.01 | -$0.02 | -$0.01 | -$0.06 |
Stats
Summary
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.
Market Cap: 103 Million
Primary Exchange: NASDAQ Global Market
Website: http://www.acelrx.com
Shares Outstanding: 50.3 Million
Float: 49.1 Million
Dividend: 0.0 (0.0%)
Beta: 2.670856
Sector: Industrials
Industry: Conglomerates
Short Interest (Jan 12, 2018): 4.77 Million
Ethical Flags
Longest drawdown: 1441 trading days
From: 2013-07-22 To: 2019-02-21
Lowest Point:
AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
via: PR Newswire at 2019-02-22 09:25:00:000
REDWOOD CITY, Calif. , Feb. 22, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results after market close on Thursday, March 7th, 2019 . AcelRx management will … read more...
Week 8 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-16 09:57:02:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +48.08% Cumulative Gain by Friday of the Week: -9.98% This week 3 out of 4 stocks reached their highs at the end of the week. Until this past Week 7, the selling of the breakout stocks prior to the end of the fix… read more...
Week 8 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-16 09:57:02:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +48.08% Cumulative Gain by Friday of the Week: -9.98% This week 3 out of 4 stocks reached their highs at the end of the week. Until this past Week 7, the selling of the breakout stocks prior to the end of the fix… read more...
Week 8 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-16 09:57:02:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +48.08% Cumulative Gain by Friday of the Week: -9.98% This week 3 out of 4 stocks reached their highs at the end of the week. Until this past Week 7, the selling of the breakout stocks prior to the end of the fix… read more...
Week 8 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-16 09:57:02:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +48.08% Cumulative Gain by Friday of the Week: -9.98% This week 3 out of 4 stocks reached their highs at the end of the week. Until this past Week 7, the selling of the breakout stocks prior to the end of the fix… read more...
Week 8 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2019-02-16 09:57:02:000
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +48.08% Cumulative Gain by Friday of the Week: -9.98% This week 3 out of 4 stocks reached their highs at the end of the week. Until this past Week 7, the selling of the breakout stocks prior to the end of the fix… read more...
Weekly Barometer: Momentum Gauges Near One-Year High As Breakouts Continue
via: SeekingAlpha at 2019-02-16 05:26:37:000
The Portfolio Barometer This article continues the weekly update on market conditions based on the types of portfolios that are outperforming or absent from the list of top-performing stocks. Portfolio strategies may experience the same autocorrelation that sustains strong price movements am… read more...
Weekly Barometer: Momentum Gauges Near One-Year High As Breakouts Continue
via: SeekingAlpha at 2019-02-16 05:26:37:000
The Portfolio Barometer This article continues the weekly update on market conditions based on the types of portfolios that are outperforming or absent from the list of top-performing stocks. Portfolio strategies may experience the same autocorrelation that sustains strong price movements am… read more...
Weekly Barometer: Momentum Gauges Near One-Year High As Breakouts Continue
via: SeekingAlpha at 2019-02-16 05:26:37:000
The Portfolio Barometer This article continues the weekly update on market conditions based on the types of portfolios that are outperforming or absent from the list of top-performing stocks. Portfolio strategies may experience the same autocorrelation that sustains strong price movements am… read more...
Weekly Barometer: Momentum Gauges Near One-Year High As Breakouts Continue
via: SeekingAlpha at 2019-02-16 05:26:37:000
The Portfolio Barometer This article continues the weekly update on market conditions based on the types of portfolios that are outperforming or absent from the list of top-performing stocks. Portfolio strategies may experience the same autocorrelation that sustains strong price movements am… read more...
Weekly Barometer: Momentum Gauges Near One-Year High As Breakouts Continue
via: SeekingAlpha at 2019-02-16 05:26:37:000
The Portfolio Barometer This article continues the weekly update on market conditions based on the types of portfolios that are outperforming or absent from the list of top-performing stocks. Portfolio strategies may experience the same autocorrelation that sustains strong price movements am… read more...
AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
via: PR Newswire at 2019-01-31 07:00:00:000
REDWOOD CITY, Calif. , Jan. 31, 2019 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a presentation about… read more...
AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
via: PR Newswire at 2019-01-31 07:00:00:000
REDWOOD CITY, Calif. , Jan. 31, 2019 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a presentation about… read more...
AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
via: PR Newswire at 2019-01-31 07:00:00:000
REDWOOD CITY, Calif. , Jan. 31, 2019 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a presentation about… read more...
Study links opioid prescriptions to marketing spend
via: SeekingAlpha at 2019-01-18 12:43:55:000
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...
Study links opioid prescriptions to marketing spend
via: SeekingAlpha at 2019-01-18 12:43:55:000
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...
Study links opioid prescriptions to marketing spend
via: SeekingAlpha at 2019-01-18 12:43:55:000
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...
Study links opioid prescriptions to marketing spend
via: SeekingAlpha at 2019-01-18 12:43:55:000
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...
Study links opioid prescriptions to marketing spend
via: SeekingAlpha at 2019-01-18 12:43:55:000
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...
Study links opioid prescriptions to marketing spend
via: SeekingAlpha at 2019-01-18 12:43:55:000
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...
Gevo, VFC among premarket gainers
via: SeekingAlpha at 2019-01-18 09:19:10:000
Gevo (NASDAQ: GEVO ) +45% on supplying its sustainable and renewable alcohol-to-jet fuel to Avfuel. More news on: Gevo, Inc., Bank OZK, V.F. Corporation, Stocks on the move, , Read more … read more...
Gevo, VFC among premarket gainers
via: SeekingAlpha at 2019-01-18 09:19:10:000
Gevo (NASDAQ: GEVO ) +45% on supplying its sustainable and renewable alcohol-to-jet fuel to Avfuel. More news on: Gevo, Inc., Bank OZK, V.F. Corporation, Stocks on the move, , Read more … read more...
Gevo, VFC among premarket gainers
via: SeekingAlpha at 2019-01-18 09:19:10:000
Gevo (NASDAQ: GEVO ) +45% on supplying its sustainable and renewable alcohol-to-jet fuel to Avfuel. More news on: Gevo, Inc., Bank OZK, V.F. Corporation, Stocks on the move, , Read more … read more...
Gevo, VFC among premarket gainers
via: SeekingAlpha at 2019-01-18 09:19:10:000
Gevo (NASDAQ: GEVO ) +45% on supplying its sustainable and renewable alcohol-to-jet fuel to Avfuel. More news on: Gevo, Inc., Bank OZK, V.F. Corporation, Stocks on the move, , Read more … read more...
Gevo, VFC among premarket gainers
via: SeekingAlpha at 2019-01-18 09:19:10:000
Gevo (NASDAQ: GEVO ) +45% on supplying its sustainable and renewable alcohol-to-jet fuel to Avfuel. More news on: Gevo, Inc., Bank OZK, V.F. Corporation, Stocks on the move, , Read more … read more...
Gevo, VFC among premarket gainers
via: SeekingAlpha at 2019-01-18 09:19:10:000
Gevo (NASDAQ: GEVO ) +45% on supplying its sustainable and renewable alcohol-to-jet fuel to Avfuel. More news on: Gevo, Inc., Bank OZK, V.F. Corporation, Stocks on the move, , Read more … read more...
Massachusetts AG after Purdue Pharma owners for role in opioid crisis
via: SeekingAlpha at 2019-01-16 07:43:42:000
Massachusetts Attorney General Maura Healey has filed an amended lawsuit against privately held Purdue Pharma aimed at holding members of the controlling Sackler family personally responsible for its role in the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIV… read more...
Massachusetts AG after Purdue Pharma owners for role in opioid crisis
via: SeekingAlpha at 2019-01-16 07:43:42:000
Massachusetts Attorney General Maura Healey has filed an amended lawsuit against privately held Purdue Pharma aimed at holding members of the controlling Sackler family personally responsible for its role in the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIV… read more...
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
via: PR Newswire at 2019-01-07 08:30:00:000
REDWOOD CITY, Calif. , Jan.7, 2019 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the… read more...
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
via: PR Newswire at 2019-01-07 08:30:00:000
REDWOOD CITY, Calif. , Jan.7, 2019 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the… read more...
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
via: PR Newswire at 2019-01-07 08:30:00:000
REDWOOD CITY, Calif. , Jan.7, 2019 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the… read more...
AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)
via: PR Newswire at 2018-12-18 07:00:00:000
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has bee… read more...
AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)
via: PR Newswire at 2018-12-18 07:00:00:000
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has bee… read more...
AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)
via: PR Newswire at 2018-12-18 07:00:00:000
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has bee… read more...
60 Minutes to air piece on opioid drugmakers and distributors Sunday
via: SeekingAlpha at 2018-12-14 13:50:08:000
CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...
60 Minutes to air piece on opioid drugmakers and distributors Sunday
via: SeekingAlpha at 2018-12-14 13:50:08:000
CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...
60 Minutes to air piece on opioid drugmakers and distributors Sunday
via: SeekingAlpha at 2018-12-14 13:50:08:000
CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...
60 Minutes to air piece on opioid drugmakers and distributors Sunday
via: SeekingAlpha at 2018-12-14 13:50:08:000
CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...
AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
via: PR Newswire at 2018-11-29 16:35:00:000
REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that… read more...
AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
via: PR Newswire at 2018-11-29 16:35:00:000
REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that… read more...
AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
via: PR Newswire at 2018-11-29 16:35:00:000
REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2018-11-20 12:40:51:000
More news on: Sphere 3D Corp., NF Energy Saving Corp., Zedge, Inc., Stocks on the move, , Read more … read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2018-11-20 12:40:51:000
More news on: Sphere 3D Corp., NF Energy Saving Corp., Zedge, Inc., Stocks on the move, , Read more … read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2018-11-20 12:40:51:000
More news on: Sphere 3D Corp., NF Energy Saving Corp., Zedge, Inc., Stocks on the move, , Read more … read more...
AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting
via: PR Newswire at 2018-11-14 16:05:00:000
REDWOOD CITY, Calif. , Nov. 14, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced an upcoming presentat… read more...
AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting
via: PR Newswire at 2018-11-14 16:05:00:000
REDWOOD CITY, Calif. , Nov. 14, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced an upcoming presentat… read more...
AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting
via: PR Newswire at 2018-11-14 16:05:00:000
REDWOOD CITY, Calif. , Nov. 14, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced an upcoming presentat… read more...
AcelRx Will Go It Alone With Dsuvia, But The Future Looks Bright
via: SeekingAlpha at 2018-11-14 11:19:12:000
After receiving FDA approval for its lead drug candidate Dsuvia last Friday, November 2, AcelRx (NASDAQ: ACRX ) held a conference call at 8:30AM EST on Monday , November 5, to discuss the company's plans going forward as a commercial-stage company. Though some observers, myself included,… read more...
AcelRx Will Go It Alone With Dsuvia, But The Future Looks Bright
via: SeekingAlpha at 2018-11-14 11:19:12:000
After receiving FDA approval for its lead drug candidate Dsuvia last Friday, November 2, AcelRx (NASDAQ: ACRX ) held a conference call at 8:30AM EST on Monday , November 5, to discuss the company's plans going forward as a commercial-stage company. Though some observers, myself included,… read more...
AcelRx Will Go It Alone With Dsuvia, But The Future Looks Bright
via: SeekingAlpha at 2018-11-14 11:19:12:000
After receiving FDA approval for its lead drug candidate Dsuvia last Friday, November 2, AcelRx (NASDAQ: ACRX ) held a conference call at 8:30AM EST on Monday , November 5, to discuss the company's plans going forward as a commercial-stage company. Though some observers, myself included,… read more...
AcelRx Pharmaceuticals prices public offering of common stock
via: SeekingAlpha at 2018-11-12 06:09:09:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) prices its public offering of 12,698,412 shares of common stock, at a price of $3.15 per share, for gross proceeds of ~$40M. More news on: AcelRx Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
AcelRx Pharmaceuticals prices public offering of common stock
via: SeekingAlpha at 2018-11-12 06:09:09:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) prices its public offering of 12,698,412 shares of common stock, at a price of $3.15 per share, for gross proceeds of ~$40M. More news on: AcelRx Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
ATVI, CTL, SWKS and YELP among premarket losers
via: SeekingAlpha at 2018-11-09 09:25:55:000
Yelp (NYSE: YELP ) -30% on Q3 earnings . More news on: Yelp, New Age Beverages Corporation, Sanchez Midstream Partners LP, Stocks on the move, , Top stock market news, Read more … read more...
ATVI, CTL, SWKS and YELP among premarket losers
via: SeekingAlpha at 2018-11-09 09:25:55:000
Yelp (NYSE: YELP ) -30% on Q3 earnings . More news on: Yelp, New Age Beverages Corporation, Sanchez Midstream Partners LP, Stocks on the move, , Top stock market news, Read more … read more...
ATVI, CTL, SWKS and YELP among premarket losers
via: SeekingAlpha at 2018-11-09 09:25:55:000
Yelp (NYSE: YELP ) -30% on Q3 earnings . More news on: Yelp, New Age Beverages Corporation, Sanchez Midstream Partners LP, Stocks on the move, , Top stock market news, Read more … read more...
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
via: PR Newswire at 2018-11-09 09:10:00:000
REDWOOD CITY, Calif. , Nov. 9, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. The gr… read more...
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
via: PR Newswire at 2018-11-09 09:10:00:000
REDWOOD CITY, Calif. , Nov. 9, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. The gr… read more...
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
via: PR Newswire at 2018-11-09 09:10:00:000
REDWOOD CITY, Calif. , Nov. 9, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. The gr… read more...
AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock
via: PR Newswire at 2018-11-09 07:00:00:000
REDWOOD CITY, Calif. , Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. AcelRx expects to grant the underwriter… read more...
AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock
via: PR Newswire at 2018-11-09 07:00:00:000
REDWOOD CITY, Calif. , Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. AcelRx expects to grant the underwriter… read more...
AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock
via: PR Newswire at 2018-11-09 07:00:00:000
REDWOOD CITY, Calif. , Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. AcelRx expects to grant the underwriter… read more...
AcelRx's DSUVIA Was Just Approved And The Stock Is Primed For A Sharp Upward Move
via: SeekingAlpha at 2018-11-08 13:21:11:000
Editor's note: Seeking Alpha is proud to welcome Trevor Springman as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Editor's… read more...
AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference
via: PR Newswire at 2018-11-07 17:19:00:000
REDWOOD CITY, Calif. , Nov. 7, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management w… read more...
Biotech Analysis Central Pharma News: Gilead's Push, AcelRx's Approval, Trevena's Rejection
via: SeekingAlpha at 2018-11-07 14:58:33:000
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gilead Sciences Makes Another Push Towards Immuno-Oncology News: Recently, Gilead Sciences ( GILD ) announced that it had formed a collaboration wi… read more...
AcelRx Pharmaceuticals, Inc. (ACRX) DSUVIA FDA Approval and AcelRx Third Quarter 2018 Conference Call (Transcript)
via: SeekingAlpha at 2018-11-05 14:40:47:000
AcelRx Pharmaceuticals, Inc. (ACRX) DSUVIA FDA Approval and AcelRx Third Quarter 2018 Conference Call November 05, 2018 08:30 AM ET Executives John Saia - General Counsel Vince Angotti - CEO Dr. Pam Palmer - Chief Medical Officer Kimberley Gaumer - VP, Regulatory Affairs and Qu… read more...
AcelRx Pharmaceuticals, Inc. (ACRX) DSUVIA FDA Approval and AcelRx Third Quarter 2018 Conference Call (Transcript)
via: SeekingAlpha at 2018-11-05 14:40:47:000
AcelRx Pharmaceuticals, Inc. (ACRX) DSUVIA FDA Approval and AcelRx Third Quarter 2018 Conference Call November 05, 2018 08:30 AM ET Executives John Saia - General Counsel Vince Angotti - CEO Dr. Pam Palmer - Chief Medical Officer Kimberley Gaumer - VP, Regulatory Affairs and Qu… read more...
Hopes Are High For AcelRx After Dsuvia Approval - Will Price Follow?
via: SeekingAlpha at 2018-11-05 11:00:58:000
In the early afternoon on Friday, November 2, AcelRx's (NASDAQ: ACRX ) shares were halted by NASDAQ pending news from the company. Around an hour later, ACRX released a press release announcing that the company's lead drug candidate Dsuvia had been approved by the FDA for the treatment of a… read more...
Hopes Are High For AcelRx After Dsuvia Approval - Will Price Follow?
via: SeekingAlpha at 2018-11-05 11:00:58:000
In the early afternoon on Friday, November 2, AcelRx's (NASDAQ: ACRX ) shares were halted by NASDAQ pending news from the company. Around an hour later, ACRX released a press release announcing that the company's lead drug candidate Dsuvia had been approved by the FDA for the treatment of a… read more...
AcelRx Pharmaceuticals misses by $0.01, misses on revenue
via: SeekingAlpha at 2018-11-02 16:09:00:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q3 GAAP EPS of -$0.21 misses by $0.01 . Revenue of $0.37M (-75.2% Y/Y) misses by $0.72M . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
AcelRx Pharmaceuticals misses by $0.01, misses on revenue
via: SeekingAlpha at 2018-11-02 16:09:00:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q3 GAAP EPS of -$0.21 misses by $0.01 . Revenue of $0.37M (-75.2% Y/Y) misses by $0.72M . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
AcelRx Pharmaceuticals misses by $0.01, misses on revenue
via: SeekingAlpha at 2018-11-02 16:09:00:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q3 GAAP EPS of -$0.21 misses by $0.01 . Revenue of $0.37M (-75.2% Y/Y) misses by $0.72M . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
via: PR Newswire at 2018-11-02 16:05:00:000
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today provided a business update and reported its third quarter 2018… read more...
AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
via: PR Newswire at 2018-11-02 16:05:00:000
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today provided a business update and reported its third quarter 2018… read more...
AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
via: PR Newswire at 2018-11-02 16:05:00:000
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today provided a business update and reported its third quarter 2018… read more...
AcelRx announces FDA approval of DSUVIA(TM)
via: PR Newswire at 2018-11-02 13:56:00:000
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, announced today the approva… read more...
AcelRx announces FDA approval of DSUVIA(TM)
via: PR Newswire at 2018-11-02 13:56:00:000
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, announced today the approva… read more...
AcelRx announces FDA approval of DSUVIA(TM)
via: PR Newswire at 2018-11-02 13:56:00:000
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, announced today the approva… read more...
Politics Wants To Get Their Vote On DSUVIA
via: SeekingAlpha at 2018-11-01 12:50:37:000
Over the past month AcelRxs ( ACRX ) stock has experienced high volatility due to a looming FDA decision on the companys lead drug DSUVIA. Typically a pending FDA approval decision generates a spike in volatility for the candidates stock; but ACRXs story is … read more...
Trevena Pushes All-In With Oliceridine
via: SeekingAlpha at 2018-11-01 09:51:54:000
Editor's note: Seeking Alpha is proud to welcome NJ Biotech Expert as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Trevena… read more...
AcelRx: A Valuation
via: SeekingAlpha at 2018-10-31 13:09:48:000
AcelRx valuation sheet - click here to download. AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX ) stock recently jumped after a positive Adcom. ACRX now shows over 95 percent improvement this year so far. However, a number of key people have questioned the addition potential of this highl… read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-26 07:42:46:000
Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-26 07:42:46:000
Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-26 07:42:46:000
Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-26 07:42:46:000
Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-26 07:42:46:000
Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Clarifying The Recent Storm Of News Related To AcelRx's Dsuvia
via: SeekingAlpha at 2018-10-24 10:04:33:000
On October 12, AcelRx (NASDAQ: ACRX ) received positive news - an FDA Advisory Committee had voted 10-3 in favor of recommending that the FDA issue official approval for ACRX's lead drug candidate Dsuvia. Despite this, as I noted in my last ACRX article , the company's stock has yet to regis… read more...
Clarifying The Recent Storm Of News Related To AcelRx's Dsuvia
via: SeekingAlpha at 2018-10-24 10:04:33:000
On October 12, AcelRx (NASDAQ: ACRX ) received positive news - an FDA Advisory Committee had voted 10-3 in favor of recommending that the FDA issue official approval for ACRX's lead drug candidate Dsuvia. Despite this, as I noted in my last ACRX article , the company's stock has yet to regis… read more...
Trump signs STOP Act aimed at opioid crisis
via: SeekingAlpha at 2018-10-24 09:24:12:000
President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...
Trump signs STOP Act aimed at opioid crisis
via: SeekingAlpha at 2018-10-24 09:24:12:000
President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare, sell-siders bullish on Gritstone Oncology
via: SeekingAlpha at 2018-10-23 08:31:49:000
Gritstone Oncology (NASDAQ: GRTS ) initiated with Buy rating and $26 (71% upside) price target at BTIG Research. Initiated with Overweight rating and $25 price target at Barclays. Initiated with Outperform rating at Cowen and Company. More news on: Gritstone Oncology, AcelRx Pharmaceutical… read more...
Premarket losers include HAS and PHG on Q3 earnings; healthcare companies down on presenting data at ESMO
via: SeekingAlpha at 2018-10-22 09:20:58:000
ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more … read more...
AcelRx Provides Updated Comments Following Positive FDA Advisory Committee Meeting
via: PR Newswire at 2018-10-19 15:15:00:000
REDWOOD CITY, Calif. , Oct. 19, 2018 /PRNewswire/ --In response to opinions expressed following the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee meeting on October 12 , AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX) stands … read more...
AcelRx Provides Updated Comments Following Positive FDA Advisory Committee Meeting
via: PR Newswire at 2018-10-19 15:15:00:000
REDWOOD CITY, Calif. , Oct. 19, 2018 /PRNewswire/ --In response to opinions expressed following the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee meeting on October 12 , AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX) stands … read more...
AcelRx Provides Updated Comments Following Positive FDA Advisory Committee Meeting
via: PR Newswire at 2018-10-19 15:15:00:000
REDWOOD CITY, Calif. , Oct. 19, 2018 /PRNewswire/ --In response to opinions expressed following the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee meeting on October 12 , AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX) stands … read more...
AcelRx Will Overcome Its Recent Stock Woes
via: SeekingAlpha at 2018-10-18 14:30:41:000
Last Friday, exactly one year after previously receiving a CRL from the FDA, AcelRx Pharmaceuticals' ( ACRX ) lead drug candidate Dsuvia received a 10-3 vote from an FDA Advisory Committee - according to the Advisory Committee, the benefits of approving Dsuvia for use in a medically supervis… read more...
Biotech Analysis Central Pharma News: Roche's Deal, AcelRX Panel Vote, Crispr And Vertex Hold Removal
via: SeekingAlpha at 2018-10-17 11:54:17:000
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Roche Enacts Deal With Ionis For Dry AMD Drug News: Recently, Roche ( RHHBY ) announced that it had formed a deal with Ionis Pharmaceuticals ( IONS )… read more...
ACRX Gets A Thumbs Up From Advisory Committee
via: SeekingAlpha at 2018-10-16 12:35:37:000
Abiword HTML Document Source AcelRx Pharmaceuticals' ( ACRX ) DSUVIA (sufentanil sublingual tablet) went under intense scrutiny by the FDAs Anesthetic and Analgesic Drug Products Advisory Committee (adcom) on Friday. After a long day of presentations and debate, the commit… read more...
DSUVIA Efficacy and Safety Data to be Presented at the American Society of Anesthesiologists (ASA) Annual Conference
via: PR Newswire at 2018-10-15 16:01:00:000
REDWOOD CITY, Calif. , Oct. 15, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced a poster … read more...
Premarket Gainers as of 9:05 am (10/15/2018)
via: SeekingAlpha at 2018-10-15 09:18:48:000
ACRX +21% on positive Ad Com vote for Dsuvia and positive analyst action . More news on: AcelRx Pharmaceuticals, Inc., Cambium Learning Group, Inc., SELLAS Life Sciences Group, Inc., Stocks on the move, , Top stock market news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-15 07:30:48:000
Argenx (NASDAQ: ARGX ) initiated with Outperform rating and $110 (51% upside) price target at Evercore ISI. More news on: Argenx SE, Elanco, KalVista Pharmaceticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Your Daily Pharma Scoop: AcelRx, How Far Can It Go; Trevena's Future
via: SeekingAlpha at 2018-10-15 07:21:49:000
AcelRx Pharma's DSUVIA backed by FDA Ad Com AcelRx Pharmaceuticals (ACRX) received the FDA Ad Com's backing by a 10-3 vote for its sufentanil sublingual tablet, DSUVIA, "for the management of moderate-to-severe pain severe enough to require an opioid analgesic and for which alternative tr… read more...
FDA Advisory Committee Recommends Approval Of DSUVIA For The Treatment Of Moderate-To-Severe Acute Pain
via: PR Newswire at 2018-10-12 16:15:00:000
REDWOOD CITY, Calif. , Oct. 12, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, announced today that the Anesthetic and Analgesic Drug Products Advi… read more...
FDA Advisory Committee Recommends Approval Of DSUVIA For The Treatment Of Moderate-To-Severe Acute Pain
via: PR Newswire at 2018-10-12 16:15:00:000
REDWOOD CITY, Calif. , Oct. 12, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, announced today that the Anesthetic and Analgesic Drug Products Advi… read more...
FDA Advisory Committee Recommends Approval Of DSUVIA For The Treatment Of Moderate-To-Severe Acute Pain
via: PR Newswire at 2018-10-12 16:15:00:000
REDWOOD CITY, Calif. , Oct. 12, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, announced today that the Anesthetic and Analgesic Drug Products Advi… read more...
FDA Ad Com backs AcelRx Pharma's Dsuvia
via: SeekingAlpha at 2018-10-12 15:37:28:000
In a 10 - 3 vote, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee recommends approval for AcelRx Pharmaceuticals' ( ACRX ) DSUVIA (sufentanil sublingual tablet) for the management of moderate-to-severe pain severe enough to require an opioid analgesic and for which altern… read more...
FDA Ad Com backs AcelRx Pharma's Dsuvia
via: SeekingAlpha at 2018-10-12 15:37:28:000
In a 10 - 3 vote, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee recommends approval for AcelRx Pharmaceuticals' ( ACRX ) DSUVIA (sufentanil sublingual tablet) for the management of moderate-to-severe pain severe enough to require an opioid analgesic and for which altern… read more...
FDA Ad Com backs AcelRx Pharma's Dsuvia
via: SeekingAlpha at 2018-10-12 15:37:28:000
In a 10 - 3 vote, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee recommends approval for AcelRx Pharmaceuticals' ( ACRX ) DSUVIA (sufentanil sublingual tablet) for the management of moderate-to-severe pain severe enough to require an opioid analgesic and for which altern… read more...
AcelRx Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review DSUVIA New Drug Application
via: PR Newswire at 2018-10-12 07:10:00:000
REDWOOD CITY, Calif. , Oct. 12, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced tha… read more...
AcelRx Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review DSUVIA New Drug Application
via: PR Newswire at 2018-10-12 07:10:00:000
REDWOOD CITY, Calif. , Oct. 12, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced tha… read more...
AcelRx Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review DSUVIA New Drug Application
via: PR Newswire at 2018-10-12 07:10:00:000
REDWOOD CITY, Calif. , Oct. 12, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced tha… read more...
Your Daily Pharma Scoop: AcelRx Briefing Docs Released, Motus GI Up On Data
via: SeekingAlpha at 2018-10-11 06:01:26:000
AcelRx Pharma (ACRX) briefing docs released , shares up after initial hiccup following misunderstanding. The FDA has released the briefing docs for AcelRx's DSUVIA ahead of the adcom Friday. The stock went down apparently because the market misunderstood some of the data - at least the au… read more...
Your Daily Pharma Scoop: Trevana Down On Briefing Docs; ACRX Is A Different Story; Ritter Up On Data
via: SeekingAlpha at 2018-10-10 17:32:40:000
Trevena down on briefing docs - what about ACRX Trevana ( TRVN ) and AcelRx ( ACRX ) have back to back adcoms this week for their pain medications. However, their two meds are quite different to each other, and it will be a mistake to base ACRX investment decisions on the fate of Trevana… read more...
Reversal of fortune for AcelRx Pharma, shares up 26% on potential Ad Com thumbs up for Dsuvia
via: SeekingAlpha at 2018-10-10 10:31:05:000
AcelRx Pharmaceuticals ( ACRX +26.4% ) is up on a 10x surge in volume on expectations of a positive vote from an FDA advisory committee this Friday related to pain med DSUVIA (sufentanil sublingual tablet). Shares were down over 50% at one time premarket before recovering. Mo… read more...
AcelRx set for down move on briefing docs for Ad Com on sufentanil sublingual tablets
via: SeekingAlpha at 2018-10-10 08:07:26:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) will likely be under pressure following the release of briefing materials for Thursday's FDA advisory committee meeting to review and discuss its marketing application seeking approval for DSUVIA (sufentanil sublingual tablet) for the management of mo… read more...
Premarket Gainers as of 9:05 am (08/10/2018)
via: SeekingAlpha at 2018-10-08 09:18:16:000
CIG +23% . More news on: Companhia Energtica de Minas Gerais - CEMIG, Petrobras - Petroleo Brasileiro S.A., India Globalization Capital, Inc, Stocks on the move, , Top stock market news, Read more … read more...
Premarket Gainers as of 9:05 am (08/10/2018)
via: SeekingAlpha at 2018-10-08 09:18:16:000
CIG +23% . More news on: Companhia Energtica de Minas Gerais - CEMIG, Petrobras - Petroleo Brasileiro S.A., India Globalization Capital, Inc, Stocks on the move, , Top stock market news, Read more … read more...
Stocks To Watch: Spotlight On Banks, Google Hardware And IPOs
via: SeekingAlpha at 2018-10-06 09:28:42:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Banks and interest rates are set to dominate the discussion next week after Treasur… read more...
Stocks To Watch: Spotlight On Banks, Google Hardware And IPOs
via: SeekingAlpha at 2018-10-06 09:28:42:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Banks and interest rates are set to dominate the discussion next week after Treasur… read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-10-05 08:59:38:000
Noteworthy events during the week of October 7 - 13 for healthcare investors. More news on: Inspire Medical Systems, Inc., OptiNose, Inc., Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
via: PR Newswire at 2018-09-25 16:05:00:000
REDWOOD CITY, Calif. , Sept. 25, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management… read more...
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
via: PR Newswire at 2018-09-25 16:05:00:000
REDWOOD CITY, Calif. , Sept. 25, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management… read more...
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
via: PR Newswire at 2018-09-25 16:05:00:000
REDWOOD CITY, Calif. , Sept. 25, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management… read more...
AcelRx Finally Has An AdCom Date. Time For A Run Up?
via: SeekingAlpha at 2018-09-13 11:15:59:000
Early on Tuesday, September 11, AcelRx Pharmaceuticals (NASDAQ: ACRX ) announced that an FDA Advisory Committee meeting will be held for the company's lead drug candidate Dsuvia on October 12. In so doing, ACRX essentially places Dsuvia's fate in the hands of the Advisory Committee - the FD… read more...
AcelRx Finally Has An AdCom Date. Time For A Run Up?
via: SeekingAlpha at 2018-09-13 11:15:59:000
Early on Tuesday, September 11, AcelRx Pharmaceuticals (NASDAQ: ACRX ) announced that an FDA Advisory Committee meeting will be held for the company's lead drug candidate Dsuvia on October 12. In so doing, ACRX essentially places Dsuvia's fate in the hands of the Advisory Committee - the FD… read more...
AcelRx Finally Has An AdCom Date. Time For A Run Up?
via: SeekingAlpha at 2018-09-13 11:15:59:000
Early on Tuesday, September 11, AcelRx Pharmaceuticals (NASDAQ: ACRX ) announced that an FDA Advisory Committee meeting will be held for the company's lead drug candidate Dsuvia on October 12. In so doing, ACRX essentially places Dsuvia's fate in the hands of the Advisory Committee - the FD… read more...
AcelRx Finally Has An AdCom Date. Time For A Run Up?
via: SeekingAlpha at 2018-09-13 11:15:59:000
Early on Tuesday, September 11, AcelRx Pharmaceuticals (NASDAQ: ACRX ) announced that an FDA Advisory Committee meeting will be held for the company's lead drug candidate Dsuvia on October 12. In so doing, ACRX essentially places Dsuvia's fate in the hands of the Advisory Committee - the FD… read more...
AcelRx Finally Has An AdCom Date. Time For A Run Up?
via: SeekingAlpha at 2018-09-13 11:15:59:000
Early on Tuesday, September 11, AcelRx Pharmaceuticals (NASDAQ: ACRX ) announced that an FDA Advisory Committee meeting will be held for the company's lead drug candidate Dsuvia on October 12. In so doing, ACRX essentially places Dsuvia's fate in the hands of the Advisory Committee - the FD… read more...
AcelRx Announces Date of FDA Advisory Committee Meeting for DSUVIA(TM)
via: PR Newswire at 2018-09-11 07:00:00:000
REDWOOD CITY, Calif. , Sept. 11, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the Anesthetic and Analgesic Drug P… read more...
AcelRx Announces Date of FDA Advisory Committee Meeting for DSUVIA(TM)
via: PR Newswire at 2018-09-11 07:00:00:000
REDWOOD CITY, Calif. , Sept. 11, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the Anesthetic and Analgesic Drug P… read more...
Senate vote approaches on bill to combat opioid crisis
via: SeekingAlpha at 2018-09-07 12:48:02:000
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...
Senate vote approaches on bill to combat opioid crisis
via: SeekingAlpha at 2018-09-07 12:48:02:000
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...
Senate vote approaches on bill to combat opioid crisis
via: SeekingAlpha at 2018-09-07 12:48:02:000
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...
Senate vote approaches on bill to combat opioid crisis
via: SeekingAlpha at 2018-09-07 12:48:02:000
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...
FDA updates on multifaceted plan to combat opioid crisis
via: SeekingAlpha at 2018-08-29 12:44:25:000
In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...
FDA updates on multifaceted plan to combat opioid crisis
via: SeekingAlpha at 2018-08-29 12:44:25:000
In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...
FDA updates on multifaceted plan to combat opioid crisis
via: SeekingAlpha at 2018-08-29 12:44:25:000
In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...
FDA clamps down on opioid-peddling websites
via: SeekingAlpha at 2018-08-28 10:57:45:000
The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc… read more...
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
via: PR Newswire at 2018-08-23 16:05:00:000
REDWOOD CITY, Calif. , Aug. 23, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that it will be … read more...
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
via: PR Newswire at 2018-08-23 16:05:00:000
REDWOOD CITY, Calif. , Aug. 23, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that it will be … read more...
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
via: PR Newswire at 2018-08-23 16:05:00:000
REDWOOD CITY, Calif. , Aug. 23, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that it will be … read more...
FDA awards contract to develop guidelines for opioid prescribing
via: SeekingAlpha at 2018-08-22 11:16:23:000
The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND… read more...
AcelRx Pharmaceuticals to Present at the 2018 Military Health System Research Symposium
via: PR Newswire at 2018-08-20 07:00:00:000
REDWOOD CITY, Calif. , Aug. 20, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that Dr. Pamela Palm… read more...
AcelRx Pharmaceuticals to Present at the 2018 Military Health System Research Symposium
via: PR Newswire at 2018-08-20 07:00:00:000
REDWOOD CITY, Calif. , Aug. 20, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that Dr. Pamela Palm… read more...
White House proposing cuts in opioid production
via: SeekingAlpha at 2018-08-16 15:24:55:000
Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...
White House proposing cuts in opioid production
via: SeekingAlpha at 2018-08-16 15:24:55:000
Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...
White House proposing cuts in opioid production
via: SeekingAlpha at 2018-08-16 15:24:55:000
Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-16 08:18:55:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) initiated with Buy rating and $7 (137% upside) price target at Ladenburg Thalmann. More news on: AcelRx Pharmaceuticals, Inc., Stryker Corporation, Teladoc Health, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-16 08:18:55:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) initiated with Buy rating and $7 (137% upside) price target at Ladenburg Thalmann. More news on: AcelRx Pharmaceuticals, Inc., Stryker Corporation, Teladoc Health, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-16 08:18:55:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) initiated with Buy rating and $7 (137% upside) price target at Ladenburg Thalmann. More news on: AcelRx Pharmaceuticals, Inc., Stryker Corporation, Teladoc Health, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
via: PR Newswire at 2018-08-08 07:00:00:000
REDWOOD CITY, Calif. , Aug. 8, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced und… read more...
AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
via: PR Newswire at 2018-08-08 07:00:00:000
REDWOOD CITY, Calif. , Aug. 8, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced und… read more...
AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
via: PR Newswire at 2018-08-08 07:00:00:000
REDWOOD CITY, Calif. , Aug. 8, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced und… read more...
AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
via: PR Newswire at 2018-08-08 07:00:00:000
REDWOOD CITY, Calif. , Aug. 8, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced und… read more...
AcelRx Provides Encouraging Q2 Update
via: SeekingAlpha at 2018-08-07 15:17:28:000
Yesterday, August 2, AcelRx Pharmaceuticals ( ACRX ) presented its second quarter update. On the whole, the update was quite positive - the company is clearly expecting approval of Dsuvia in November and has already hired sales representatives and developed a strategic, well-researched marketi… read more...
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 21:33:16:000
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2018 Earnings Conference Call August 02, 2018 4:30 PM ET Executives Vince Angotti - Chief Executive Officer Pamela Palmer - Co-Founder and Chief Medical Officer Raffi Asadorian - Chief Financial Officer John Saia - General Counsel Analy… read more...
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 21:33:16:000
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2018 Earnings Conference Call August 02, 2018 4:30 PM ET Executives Vince Angotti - Chief Executive Officer Pamela Palmer - Co-Founder and Chief Medical Officer Raffi Asadorian - Chief Financial Officer John Saia - General Counsel Analy… read more...
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 21:33:16:000
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2018 Earnings Conference Call August 02, 2018 4:30 PM ET Executives Vince Angotti - Chief Executive Officer Pamela Palmer - Co-Founder and Chief Medical Officer Raffi Asadorian - Chief Financial Officer John Saia - General Counsel Analy… read more...
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 21:33:16:000
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2018 Earnings Conference Call August 02, 2018 4:30 PM ET Executives Vince Angotti - Chief Executive Officer Pamela Palmer - Co-Founder and Chief Medical Officer Raffi Asadorian - Chief Financial Officer John Saia - General Counsel Analy… read more...
AcelRx Pharmaceuticals EPS in-line, misses on revenue
via: SeekingAlpha at 2018-08-02 16:05:00:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q2 EPS of -$0.20 in-line. More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results
via: PR Newswire at 2018-08-02 16:01:00:000
REDWOOD CITY, Calif. , Aug. 2, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today reported its second quarter 2018 financial results. "The fir… read more...
Cheap AcelRx Options Minimize Risk And Maximize Potential Profit
via: SeekingAlpha at 2018-07-19 11:55:13:000
Before I dive into this strategy, I'd like to make it clear at the outset that this strategy is quite speculative. That being said, I believe that it offers a very outsized risk-reward ratio, and the assumptions/predictions on which it is based are reasonable and sound. Strategy Rationale … read more...
Cheap AcelRx Options Minimize Risk And Maximize Potential Profit
via: SeekingAlpha at 2018-07-19 11:55:13:000
Before I dive into this strategy, I'd like to make it clear at the outset that this strategy is quite speculative. That being said, I believe that it offers a very outsized risk-reward ratio, and the assumptions/predictions on which it is based are reasonable and sound. Strategy Rationale … read more...
Cheap AcelRx Options Minimize Risk And Maximize Potential Profit
via: SeekingAlpha at 2018-07-19 11:55:13:000
Before I dive into this strategy, I'd like to make it clear at the outset that this strategy is quite speculative. That being said, I believe that it offers a very outsized risk-reward ratio, and the assumptions/predictions on which it is based are reasonable and sound. Strategy Rationale … read more...
Cheap AcelRx Options Minimize Risk And Maximize Potential Profit
via: SeekingAlpha at 2018-07-19 11:55:13:000
Before I dive into this strategy, I'd like to make it clear at the outset that this strategy is quite speculative. That being said, I believe that it offers a very outsized risk-reward ratio, and the assumptions/predictions on which it is based are reasonable and sound. Strategy Rationale … read more...
Cheap AcelRx Options Minimize Risk And Maximize Potential Profit
via: SeekingAlpha at 2018-07-19 11:55:13:000
Before I dive into this strategy, I'd like to make it clear at the outset that this strategy is quite speculative. That being said, I believe that it offers a very outsized risk-reward ratio, and the assumptions/predictions on which it is based are reasonable and sound. Strategy Rationale … read more...
Cheap AcelRx Options Minimize Risk And Maximize Potential Profit
via: SeekingAlpha at 2018-07-19 11:55:13:000
Before I dive into this strategy, I'd like to make it clear at the outset that this strategy is quite speculative. That being said, I believe that it offers a very outsized risk-reward ratio, and the assumptions/predictions on which it is based are reasonable and sound. Strategy Rationale … read more...
AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018
via: PR Newswire at 2018-07-19 08:33:00:000
REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 2nd, 2018 . AcelRx management will host an in… read more...
AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018
via: PR Newswire at 2018-07-19 08:33:00:000
REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 2nd, 2018 . AcelRx management will host an in… read more...
AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018
via: PR Newswire at 2018-07-19 08:33:00:000
REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 2nd, 2018 . AcelRx management will host an in… read more...
AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018
via: PR Newswire at 2018-07-19 08:33:00:000
REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 2nd, 2018 . AcelRx management will host an in… read more...
AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018
via: PR Newswire at 2018-07-19 08:33:00:000
REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 2nd, 2018 . AcelRx management will host an in… read more...
AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018
via: PR Newswire at 2018-07-19 08:33:00:000
REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 2nd, 2018 . AcelRx management will host an in… read more...
AcelRX - The Military Angle That Could Boost Its Prospects
via: SeekingAlpha at 2018-07-16 04:18:24:000
Last year, the Pentagon led a revolt against the FDAs delay in approving a freeze-dried plasma product that they thought would be critical to soldiers in combat. The Pentagon passed a bill allowing them to use unapproved products under certain circumstances - or, in other words, to c… read more...
AcelRX - The Military Angle That Could Boost Its Prospects
via: SeekingAlpha at 2018-07-16 04:18:24:000
Last year, the Pentagon led a revolt against the FDAs delay in approving a freeze-dried plasma product that they thought would be critical to soldiers in combat. The Pentagon passed a bill allowing them to use unapproved products under certain circumstances - or, in other words, to c… read more...
AcelRX - The Military Angle That Could Boost Its Prospects
via: SeekingAlpha at 2018-07-16 04:18:24:000
Last year, the Pentagon led a revolt against the FDAs delay in approving a freeze-dried plasma product that they thought would be critical to soldiers in combat. The Pentagon passed a bill allowing them to use unapproved products under certain circumstances - or, in other words, to c… read more...
After Hours Gainers / Losers (07/13/2018)
via: SeekingAlpha at 2018-07-13 17:39:21:000
Top Gainers: NEW +2.0% . VIRT +1.9% . XOG +1.7% . ACRX +1.5% . DNR +1.4% . More news on: Puxin, Virtu Financial, Inc., Extraction Oil & Gas, Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (07/13/2018)
via: SeekingAlpha at 2018-07-13 17:39:21:000
Top Gainers: NEW +2.0% . VIRT +1.9% . XOG +1.7% . ACRX +1.5% . DNR +1.4% . More news on: Puxin, Virtu Financial, Inc., Extraction Oil & Gas, Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (07/13/2018)
via: SeekingAlpha at 2018-07-13 17:39:21:000
Top Gainers: NEW +2.0% . VIRT +1.9% . XOG +1.7% . ACRX +1.5% . DNR +1.4% . More news on: Puxin, Virtu Financial, Inc., Extraction Oil & Gas, Stocks on the move, , News on ETFs, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-07-13 07:30:54:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) initiated with Market Perform rating at Oppenheimer. More news on: AcelRx Pharmaceuticals, Inc., ADMA Biologics Inc, Avenue Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-07-13 07:30:54:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) initiated with Market Perform rating at Oppenheimer. More news on: AcelRx Pharmaceuticals, Inc., ADMA Biologics Inc, Avenue Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-07-13 07:30:54:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) initiated with Market Perform rating at Oppenheimer. More news on: AcelRx Pharmaceuticals, Inc., ADMA Biologics Inc, Avenue Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...
Midday Gainers / Losers (07/12/2018)
via: SeekingAlpha at 2018-07-12 12:44:54:000
Gainers: CNTF +70% . GLMD +26% . FPI +23% . AMBO +22% . PBSK +21% . OPNT +18% . CA +18% . ZGNX +18% . JAGX +17% . BLFS +14% . More news on: China TechFaith Wireless Communication Technology Limited, Galmed Pharmaceuticals Ltd., Farmland Partners Inc, Stocks… read more...
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
via: PR Newswire at 2018-07-12 09:30:00:000
REDWOOD CITY, Calif. , July 12, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 7,272,727 shares of its common stock, at a public offering price of $2.75 per share. The gross pr… read more...
Premarket Losers as of 9:05 am (07/12/2018)
via: SeekingAlpha at 2018-07-12 09:20:55:000
SSLJ -38% . More news on: SSLJ. COM LTD, SELLAS Life Sciences Group, Inc., Biocept, Inc., Stocks on the move, Read more … read more...
After Hours Gainers / Losers (07/11/2018)
via: SeekingAlpha at 2018-07-11 17:36:07:000
Top gainers: CA +15.7% . WFT +5.7% . FPI +3.2%. BHGE +2.8% . AUPH +2.5% . More news on: CA Inc., Weatherford International Ltd., Farmland Partners Inc, Stocks on the move, , News on ETFs, Read more … read more...
AcelRx Pharmaceuticals Announces Commencement of Public Offering of Common Stock
via: PR Newswire at 2018-07-11 16:07:00:000
REDWOOD CITY, Calif. , July 11, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it has commenced an underwritten public offering of shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an add… read more...
AcelRx +3.9% on EC approval for Dzuveo
via: SeekingAlpha at 2018-06-27 09:13:44:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) announces that the European Commission has approved Dzuveo (or Dsuvia in the US) for managing acute moderate to severe pain in adults in medically monitored settings. More news on: AcelRx Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the… read more...
AcelRx +3.9% on EC approval for Dzuveo
via: SeekingAlpha at 2018-06-27 09:13:44:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) announces that the European Commission has approved Dzuveo (or Dsuvia in the US) for managing acute moderate to severe pain in adults in medically monitored settings. More news on: AcelRx Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the… read more...
AcelRx +3.9% on EC approval for Dzuveo
via: SeekingAlpha at 2018-06-27 09:13:44:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) announces that the European Commission has approved Dzuveo (or Dsuvia in the US) for managing acute moderate to severe pain in adults in medically monitored settings. More news on: AcelRx Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the… read more...
AcelRx receives European Commission approval for DZUVEO(TM)
via: PR Newswire at 2018-06-27 07:00:00:000
REDWOOD CITY, Calif. , June 27, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the European Commission (EC) ha… read more...
AcelRx receives European Commission approval for DZUVEO(TM)
via: PR Newswire at 2018-06-27 07:00:00:000
REDWOOD CITY, Calif. , June 27, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the European Commission (EC) ha… read more...
AcelRx receives European Commission approval for DZUVEO(TM)
via: PR Newswire at 2018-06-27 07:00:00:000
REDWOOD CITY, Calif. , June 27, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the European Commission (EC) ha… read more...
AcelRx Sparks Investor Interest As It Gears Up For Another Shot With Dsuvia
via: SeekingAlpha at 2018-06-17 17:16:28:000
Last year, AcelRx Pharmaceuticals ( ACRX ) made a remarkable run, catapulting itself onto many investors' watch lists. After trading under $3.00 for most of the first half of 2017, ACRX began to pick up steam in July 2017, after Jefferies initiated coverage on the stock with a Buy rating . In… read more...
AcelRx Sparks Investor Interest As It Gears Up For Another Shot With Dsuvia
via: SeekingAlpha at 2018-06-17 17:16:28:000
Last year, AcelRx Pharmaceuticals ( ACRX ) made a remarkable run, catapulting itself onto many investors' watch lists. After trading under $3.00 for most of the first half of 2017, ACRX began to pick up steam in July 2017, after Jefferies initiated coverage on the stock with a Buy rating . In… read more...
AcelRx Sparks Investor Interest As It Gears Up For Another Shot With Dsuvia
via: SeekingAlpha at 2018-06-17 17:16:28:000
Last year, AcelRx Pharmaceuticals ( ACRX ) made a remarkable run, catapulting itself onto many investors' watch lists. After trading under $3.00 for most of the first half of 2017, ACRX began to pick up steam in July 2017, after Jefferies initiated coverage on the stock with a Buy rating . In… read more...
After Hours Gainers / Losers (06/11/2018)
via: SeekingAlpha at 2018-06-11 17:38:10:000
Top gainers: RH +19.0% . PLAY +14.0% . URBN +5.3% . KMG +4.2% . ACRX +4.3% . More news on: RH, Dave & Buster's Entertainment, Inc., Urban Outfitters, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (06/11/2018)
via: SeekingAlpha at 2018-06-11 17:38:10:000
Top gainers: RH +19.0% . PLAY +14.0% . URBN +5.3% . KMG +4.2% . ACRX +4.3% . More news on: RH, Dave & Buster's Entertainment, Inc., Urban Outfitters, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (06/11/2018)
via: SeekingAlpha at 2018-06-11 17:38:10:000
Top gainers: RH +19.0% . PLAY +14.0% . URBN +5.3% . KMG +4.2% . ACRX +4.3% . More news on: RH, Dave & Buster's Entertainment, Inc., Urban Outfitters, Inc., Stocks on the move, , News on ETFs, Read more … read more...
An Integrated BioSci Rounds Report: Madrigal Continued Its Rally While Improving FDA Policy To Benefit Nektar
via: SeekingAlpha at 2018-06-07 05:40:53:000
When a better tool or idea or approach comes along, what could be better than to swap it for your old, less useful tool? Warren Buffett and I routinely do this, but most people, as Galbraith says, forever cling to their old, less useful tools. - Charlie Munger Trading Analytics Welcome t… read more...
An Integrated BioSci Rounds Report: Madrigal Continued Its Rally While Improving FDA Policy To Benefit Nektar
via: SeekingAlpha at 2018-06-07 05:40:53:000
When a better tool or idea or approach comes along, what could be better than to swap it for your old, less useful tool? Warren Buffett and I routinely do this, but most people, as Galbraith says, forever cling to their old, less useful tools. - Charlie Munger Trading Analytics Welcome t… read more...
An Integrated BioSci Rounds Report: Madrigal Continued Its Rally While Improving FDA Policy To Benefit Nektar
via: SeekingAlpha at 2018-06-07 05:40:53:000
When a better tool or idea or approach comes along, what could be better than to swap it for your old, less useful tool? Warren Buffett and I routinely do this, but most people, as Galbraith says, forever cling to their old, less useful tools. - Charlie Munger Trading Analytics Welcome t… read more...
Top 10 Market Movers With Insider Buying As Of May 29, 2018
via: SeekingAlpha at 2018-05-31 10:43:59:000
There are many ways to use insider transactions to help guide your investing strategies that don't rely on just the dollar amount of the transaction. While dollar amount should always be considered when ranking an insider purchase, here are a few other things to consider: How much has the … read more...
Top 10 Market Movers With Insider Buying As Of May 29, 2018
via: SeekingAlpha at 2018-05-31 10:43:59:000
There are many ways to use insider transactions to help guide your investing strategies that don't rely on just the dollar amount of the transaction. While dollar amount should always be considered when ranking an insider purchase, here are a few other things to consider: How much has the … read more...
Top 10 Market Movers With Insider Buying As Of May 29, 2018
via: SeekingAlpha at 2018-05-31 10:43:59:000
There are many ways to use insider transactions to help guide your investing strategies that don't rely on just the dollar amount of the transaction. While dollar amount should always be considered when ranking an insider purchase, here are a few other things to consider: How much has the … read more...
Redux: My 3 January Effect Candidates Are Producing Major Alpha Through May
via: SeekingAlpha at 2018-05-30 13:51:36:000
Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron ( GERN ), Antares Pharma ( ATRS ) and AcelRX ( ACRX ). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold… read more...
Redux: My 3 January Effect Candidates Are Producing Major Alpha Through May
via: SeekingAlpha at 2018-05-30 13:51:36:000
Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron ( GERN ), Antares Pharma ( ATRS ) and AcelRX ( ACRX ). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold… read more...
Redux: My 3 January Effect Candidates Are Producing Major Alpha Through May
via: SeekingAlpha at 2018-05-30 13:51:36:000
Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron ( GERN ), Antares Pharma ( ATRS ) and AcelRX ( ACRX ). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold… read more...
3 Things In Biotech, May 28: Making Deals In The Asian Market
via: SeekingAlpha at 2018-05-28 06:38:25:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Karyopharm strikes a deal that can help them in Asia Company: Karyopharm ( KPTI ) Ther… read more...
3 Things In Biotech, May 28: Making Deals In The Asian Market
via: SeekingAlpha at 2018-05-28 06:38:25:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Karyopharm strikes a deal that can help them in Asia Company: Karyopharm ( KPTI ) Ther… read more...
3 Things In Biotech, May 28: Making Deals In The Asian Market
via: SeekingAlpha at 2018-05-28 06:38:25:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Karyopharm strikes a deal that can help them in Asia Company: Karyopharm ( KPTI ) Ther… read more...
Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study
via: SeekingAlpha at 2018-05-27 19:15:05:000
Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...
Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study
via: SeekingAlpha at 2018-05-27 19:15:05:000
Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...
Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study
via: SeekingAlpha at 2018-05-27 19:15:05:000
Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...
Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study
via: SeekingAlpha at 2018-05-27 19:15:05:000
Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a traders dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one… read more...
Your Daily Pharma Scoop: Esperion Shows Positive Data, Clementia's Palovarotene, Insmed's ALIS
via: SeekingAlpha at 2018-05-24 12:00:00:000
Analysis focus: ESPR Esperion Therapeutics (ESPR) key attraction is that the market that its lead candidate targets - LDL-C reduction - once had Lipitor, a drug that generated $13bn at peak for Pfizer (PFE). The difference is that Lipitor and a number of similar drugs are statins, … read more...
Your Daily Pharma Scoop: Esperion Shows Positive Data, Clementia's Palovarotene, Insmed's ALIS
via: SeekingAlpha at 2018-05-24 12:00:00:000
Analysis focus: ESPR Esperion Therapeutics (ESPR) key attraction is that the market that its lead candidate targets - LDL-C reduction - once had Lipitor, a drug that generated $13bn at peak for Pfizer (PFE). The difference is that Lipitor and a number of similar drugs are statins, … read more...
Your Daily Pharma Scoop: Esperion Shows Positive Data, Clementia's Palovarotene, Insmed's ALIS
via: SeekingAlpha at 2018-05-24 12:00:00:000
Analysis focus: ESPR Esperion Therapeutics (ESPR) key attraction is that the market that its lead candidate targets - LDL-C reduction - once had Lipitor, a drug that generated $13bn at peak for Pfizer (PFE). The difference is that Lipitor and a number of similar drugs are statins, … read more...
Premarket Gainers as of 9:05 am (05/24/2018)
via: SeekingAlpha at 2018-05-24 09:21:48:000
SBOT +27% on robustness of protein manufacturing process. More news on: Stellar Biotechnologies Inc., Babcock & Wilcox Enterprises, Inc., Williams-Sonoma Inc., Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (05/24/2018)
via: SeekingAlpha at 2018-05-24 09:21:48:000
SBOT +27% on robustness of protein manufacturing process. More news on: Stellar Biotechnologies Inc., Babcock & Wilcox Enterprises, Inc., Williams-Sonoma Inc., Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (05/24/2018)
via: SeekingAlpha at 2018-05-24 09:21:48:000
SBOT +27% on robustness of protein manufacturing process. More news on: Stellar Biotechnologies Inc., Babcock & Wilcox Enterprises, Inc., Williams-Sonoma Inc., Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (05/24/2018)
via: SeekingAlpha at 2018-05-24 09:21:48:000
SBOT +27% on robustness of protein manufacturing process. More news on: Stellar Biotechnologies Inc., Babcock & Wilcox Enterprises, Inc., Williams-Sonoma Inc., Stocks on the move, Read more … read more...
AcelRx announces FDA acceptance of NDA for DSUVIA
via: PR Newswire at 2018-05-24 07:00:00:000
REDWOOD CITY, Calif. , May 24, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the acceptance of its New Drug Applic… read more...
AcelRx announces FDA acceptance of NDA for DSUVIA
via: PR Newswire at 2018-05-24 07:00:00:000
REDWOOD CITY, Calif. , May 24, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the acceptance of its New Drug Applic… read more...
AcelRx announces FDA acceptance of NDA for DSUVIA
via: PR Newswire at 2018-05-24 07:00:00:000
REDWOOD CITY, Calif. , May 24, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the acceptance of its New Drug Applic… read more...
AcelRx announces FDA acceptance of NDA for DSUVIA
via: PR Newswire at 2018-05-24 07:00:00:000
REDWOOD CITY, Calif. , May 24, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the acceptance of its New Drug Applic… read more...
Leerink-led investors acquire Three Arch stake in AcelRx; shares up 7%
via: SeekingAlpha at 2018-05-23 12:08:41:000
AcelRx Pharmaceuticals ( ACRX +6.9% ) is up on average volume on the heels of its announcement that the ~9.4M shares owned by funds managed by Three Arch Partners have been acquired by investors led by Leerink Revelation Partners and Industry Ventures. More news on: AcelRx Pharmaceutic… read more...
Leerink-led investors acquire Three Arch stake in AcelRx; shares up 7%
via: SeekingAlpha at 2018-05-23 12:08:41:000
AcelRx Pharmaceuticals ( ACRX +6.9% ) is up on average volume on the heels of its announcement that the ~9.4M shares owned by funds managed by Three Arch Partners have been acquired by investors led by Leerink Revelation Partners and Industry Ventures. More news on: AcelRx Pharmaceutic… read more...
Leerink-led investors acquire Three Arch stake in AcelRx; shares up 7%
via: SeekingAlpha at 2018-05-23 12:08:41:000
AcelRx Pharmaceuticals ( ACRX +6.9% ) is up on average volume on the heels of its announcement that the ~9.4M shares owned by funds managed by Three Arch Partners have been acquired by investors led by Leerink Revelation Partners and Industry Ventures. More news on: AcelRx Pharmaceutic… read more...
Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures
via: PR Newswire at 2018-05-23 07:00:00:000
REDWOOD CITY, Calif. , May 23, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that all of AcelRx shares owned by Three A… read more...
Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures
via: PR Newswire at 2018-05-23 07:00:00:000
REDWOOD CITY, Calif. , May 23, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that all of AcelRx shares owned by Three A… read more...
Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures
via: PR Newswire at 2018-05-23 07:00:00:000
REDWOOD CITY, Calif. , May 23, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that all of AcelRx shares owned by Three A… read more...
AcelRx Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
via: PR Newswire at 2018-05-22 11:45:00:000
REDWOOD CITY, Calif. , May 22, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Vince Ang… read more...
FDA OKs first non-opioid treatment for opioid withdrawal
via: SeekingAlpha at 2018-05-16 16:44:42:000
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read … read more...
FDA OKs first non-opioid treatment for opioid withdrawal
via: SeekingAlpha at 2018-05-16 16:44:42:000
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read … read more...
After Hours Gainers / Losers (05/15/2018)
via: SeekingAlpha at 2018-05-15 17:35:14:000
Top gainers: BOOT +8.4% . ACRX +3.6% . EBIO +3.4% . PETQ +3.1% . SUPV +2.8% . More news on: Boot Barn Holdings, AcelRx Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (05/15/2018)
via: SeekingAlpha at 2018-05-15 17:35:14:000
Top gainers: BOOT +8.4% . ACRX +3.6% . EBIO +3.4% . PETQ +3.1% . SUPV +2.8% . More news on: Boot Barn Holdings, AcelRx Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (05/15/2018)
via: SeekingAlpha at 2018-05-15 17:35:14:000
Top gainers: BOOT +8.4% . ACRX +3.6% . EBIO +3.4% . PETQ +3.1% . SUPV +2.8% . More news on: Boot Barn Holdings, AcelRx Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (05/15/2018)
via: SeekingAlpha at 2018-05-15 17:35:14:000
Top gainers: BOOT +8.4% . ACRX +3.6% . EBIO +3.4% . PETQ +3.1% . SUPV +2.8% . More news on: Boot Barn Holdings, AcelRx Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , News on ETFs, Read more … read more...
Your Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed Data
via: SeekingAlpha at 2018-05-10 10:00:00:000
Analysis focus: ACRX If you recall your AcelRx (NASDAQ: ACRX ), it got a CRL for DSUVIA lasy year citing safety concerns and drug administration issues. The exact things the FDA said, as reported by the company, were: The two primary recommendations within the CRL are: first, while… read more...
Your Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed Data
via: SeekingAlpha at 2018-05-10 10:00:00:000
Analysis focus: ACRX If you recall your AcelRx (NASDAQ: ACRX ), it got a CRL for DSUVIA lasy year citing safety concerns and drug administration issues. The exact things the FDA said, as reported by the company, were: The two primary recommendations within the CRL are: first, while… read more...
AcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-09 19:27:03:000
AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2018 Earnings Conference Call May 9, 2018 04:30 PM ET Executives Vince Angotti - CEO Pamela Palmer - Co-Founder and Chief Medical Officer Raffi Asadorian - CFO John Saia - General Counsel Analysts Randall Stanicky - RBC Capital Marke… read more...
AcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-09 19:27:03:000
AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2018 Earnings Conference Call May 9, 2018 04:30 PM ET Executives Vince Angotti - CEO Pamela Palmer - Co-Founder and Chief Medical Officer Raffi Asadorian - CFO John Saia - General Counsel Analysts Randall Stanicky - RBC Capital Marke… read more...
AcelRx Pharmaceuticals beats by $0.01, misses on revenue
via: SeekingAlpha at 2018-05-09 16:09:32:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q1 EPS of -$0.23 beats by $0.01 . Revenue of $0.34M (-89.1% Y/Y) misses by $0.81M . Shares +2% . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , read more...
AcelRx Pharmaceuticals beats by $0.01, misses on revenue
via: SeekingAlpha at 2018-05-09 16:09:32:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q1 EPS of -$0.23 beats by $0.01 . Revenue of $0.34M (-89.1% Y/Y) misses by $0.81M . Shares +2% . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , read more...
AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results
via: PR Newswire at 2018-05-09 16:05:00:000
REDWOOD CITY, Calif. , May 9, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today reported its first quarter 2018 financial results. "The… read more...
AcelRx refiles U.S. marketing application for Dsuvia, action date Q4; shares up 10% premarket
via: SeekingAlpha at 2018-05-09 08:43:55:000
AcelRx Pharmaceuticals (NASDAQ: ACRX ) is up 10% premarket on light volume on the heels of its announcement that it has resubmitted its marketing application to the FDA seeking approval for pain med DSUVIA (sufentanil sublingual tablet, 30 mcg). More news on: AcelRx Pharmaceu… read more...
AcelRx resubmits New Drug Application for DSUVIA(TM)
via: PR Newswire at 2018-05-09 07:00:00:000
REDWOOD CITY, Calif. , May 9, 2018 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the resubmission of the New Drug Appli… read more...
AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems
via: PR Newswire at 2018-04-30 07:00:00:000
REDWOOD CITY, Calif. , April 30, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of two s… read more...
AcelRx receives positive CHMP opinion for DZUVEO(TM) for management of acute moderate to severe pain in medically monitored settings
via: PR Newswire at 2018-04-27 07:20:00:000
REDWOOD CITY, Calif. , April 27, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the Committee for Medicinal Product… read more...
Opioid prescriptions dropped 12% in 2017
via: SeekingAlpha at 2018-04-26 03:18:20:000
Opioid prescriptions dropped 12% in 2017, according to a report from the IQVIA Institute for Human Data Science. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more … read more...
Wall Street Breakfast: Infrastructure Details Coming Today
via: SeekingAlpha at 2018-02-12 07:07:40:000
The White House will roll out a long-awaited infrastructure plan today, which already faces hurdles in Congress because it doesn't offer as much new federal funding as Democrats want, or directly address how to pay for the effort. President Trump will propose spending $200B over 10… read more...
Wall Street Breakfast: Infrastructure Details Coming Today
via: SeekingAlpha at 2018-02-12 07:07:40:000
The White House will roll out a long-awaited infrastructure plan today, which already faces hurdles in Congress because it doesn't offer as much new federal funding as Democrats want, or directly address how to pay for the effort. President Trump will propose spending $200B over 10… read more...
OxyContin maker stops promoting opioids
via: SeekingAlpha at 2018-02-11 07:37:10:000
OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...
OxyContin maker stops promoting opioids
via: SeekingAlpha at 2018-02-11 07:37:10:000
OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...
OxyContin maker stops promoting opioids
via: SeekingAlpha at 2018-02-11 07:37:10:000
OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...
3 Biotechs For The January Effect
via: SeekingAlpha at 2018-01-03 10:58:25:000
Microcaps and Biotechs may be the perfect formula for portfolio jet fuel in early 2018 If you want to increase your odds of finding alpha in your portfolio performance, you need to look beyond indexing and diversified large caps ( SPY ) ( VOO ) to find special situations where potential rewa… read more...
AcelRx Stock Looks Weak Ahead Of Revised NDA Submissions For Two Products
via: SeekingAlpha at 2017-12-29 09:05:18:000
AcelRx Pharmaceuticals, Inc. ( ACRX ) stock lost all its gains made till October after it posted a steep decline that month. The company's lead drug candidate received a CRL from the FDA, derailing the timeline for its commercialization. Further, the CRL also raised doubts about management e… read more...
After Hours Gainers / Losers
via: SeekingAlpha at 2017-11-22 17:36:45:000
Top gainers: SD +6.3% . UEPS +3.5% . ENIC +3.3% . XNET +2.7% . VERI +2.3% . More news on: SandRidge Energy, Inc., Net 1 UEPS Technologies, Inc., Xunlei Limited, Stocks on the move, Read more … read more...
FDA issues guidance on development of generic abuse-deterrent opioids
via: SeekingAlpha at 2017-11-21 14:00:19:000
In a statement , FDA Commissioner Scott Gottlieb, M.D. says the agency is taking steps to help drug makers develop approvable generic opioid medications that incorporate abuse-deterrent characteristics. More news on: Teva Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited… read more...
Cost of U.S. opioid epidemic tops $500B
via: SeekingAlpha at 2017-11-20 04:58:46:000
In an analysis to be released today, the White House will say the true cost of the opioid drug epidemic in 2015 was $504B, more than six times larger than the most recent estimate. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Health… read more...
Your Daily Pharma Scoop: A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tumbles
via: SeekingAlpha at 2017-11-16 14:35:00:000
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Sanofi Today we will discuss an art… read more...
AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain
via: PR Newswire at 2017-11-16 07:00:00:000
REDWOOD CITY, Calif. , Nov. 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a m… read more...
Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered
via: SeekingAlpha at 2017-11-15 16:46:51:000
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today we will … read more...
Premarket Losers as of 9:05 am
via: SeekingAlpha at 2017-11-10 09:17:03:000
RELY -38% . More news on: Real Industry, Inc., Neovasc Inc., Infinity Pharmaceuticals, Inc., Stocks on the move, Read more … read more...
AcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q3 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2017-11-09 23:19:08:000
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2017 Earnings Conference Call November 09, 2017 04:30 PM ET Executives Jane Wright-Mitchell - Chief Legal Officer Vince Angotti - CEO Pam Palmer - Chief Medical Officer Raffi Asadorian - CFO Analysts Randall Stanicky - RBC Capital Ma… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|